{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:27:56Z","timestamp":1793384876434,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T00:00:00Z","timestamp":1670112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nature Science Foundation of Shandong Province","award":["ZR2019PH118"],"award-info":[{"award-number":["ZR2019PH118"]}]},{"name":"major vector-borne pathogens in the Belt and Road","award":["2018ZX10101002-002"],"award-info":[{"award-number":["2018ZX10101002-002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81602904"],"award-info":[{"award-number":["81602904"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Artemisinin-based combination therapy (ACT) has been recommended as the first-line treatment by the World Health Organization to treat uncomplicated <jats:italic>Plasmodium falciparum<\/jats:italic> malaria. However, the emergence and spread of <jats:italic>P. falciparum<\/jats:italic> resistant to artemisinins and their partner drugs is a significant risk for the global effort to reduce disease burden facing the world. Currently, dihydroartemisinin-piperaquine (DHA-PPQ) is the most common drug used to treat <jats:italic>P. falciparum<\/jats:italic>, but little evidence about the resistance status targeting DHA (ACT drug) and its partner drug (PPQ) has been reported in Shandong Province, China.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective study was conducted to explore the prevalence and spatial distribution of <jats:italic>Pfk13<\/jats:italic> and <jats:italic>Pfcrt<\/jats:italic> polymorphisms (sites of 72\u201376, and 93\u2013356) among imported <jats:italic>P. falciparum<\/jats:italic> isolates between years 2015\u20132019 in Shandong Province in eastern China. Individual epidemiological information was collected from a web-based reporting system were reviewed and analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 425 <jats:italic>P. falciparum<\/jats:italic> blood samples in 2015\u20132019 were included and 7.3% (31\/425) carried <jats:italic>Pfk13<\/jats:italic> mutations. Out of the isolates that carried <jats:italic>Pfk13<\/jats:italic> mutations, 54.8% (17\/31) were nonsynonymous polymorphisms. The mutant alleles A578S, Q613H, C469C, and S549S in <jats:italic>Pfk13<\/jats:italic> were the more frequently detected allele, the mutation rate was the same as 9.7% (3\/31). Another allele <jats:italic>Pfk13<\/jats:italic> C580Y, closely associated with artemisinin (ART) resistance, was found as 3.2% (2\/31), which was found in Cambodia. A total of 14 mutant isolates were identified in Western Africa countries (45.2%, 14\/31). For the <jats:italic>Pfcrt<\/jats:italic> gene, the mutation rate was 18.1% (77\/425). T<jats:sub>76<\/jats:sub>T<jats:sub>356<\/jats:sub> and T<jats:sub>76<\/jats:sub> were more frequent in all 13 different haplotypes with 26.0% (20\/77) and 23.4% (18\/77). The CVIET and CVIKT mutant at loci 72\u201376 have exhibited a prevalence of 19.5% (15\/77) and 3.9% (3\/77), respectively. The CVIET was mainly observed in samples from Congo (26.7%, 4\/15) and Mozambique (26.7%, 4\/15). No mutations were found at loci 97, 101 and 145. For polymorphisms at locus 356, a total of 24 isolates were identified and mainly from Congo (29.2%, 7\/24).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings indicate a low prevalence of <jats:italic>Pfk13<\/jats:italic> in the African isolates. However, the emergence and increase in the new alleles <jats:italic>Pfcrt<\/jats:italic> I356T, reveals a potential risk of drug pressure in PPQ among migrant workers returned from Africa. Therefore, continuous molecular surveillance of <jats:italic>Pfcrt<\/jats:italic> mutations and in vitro susceptibility tests related to PPQ are necessary.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04398-x","type":"journal-article","created":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T06:02:33Z","timestamp":1670133753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Molecular surveillance of artemisinin resistance-related Pfk13 and pfcrt polymorphisms in imported Plasmodium falciparum isolates reported in eastern China from 2015 to 2019"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiangli","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuisen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,4]]},"reference":[{"key":"4398_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/B978-0-12-800869-0.00009-3","volume":"86","author":"J Feng","year":"2014","unstructured":"Feng J, Xia ZG, Vong S, Yang WZ, Zhou SS, Xiao N. Preparedness for malaria resurgence in China: case study on imported cases in 2000\u20132012. Adv Parasitol. 2014;86:231\u201365.","journal-title":"Adv Parasitol"},{"key":"4398_CR2","unstructured":"National Health Commission. Chinese report on Malaria Elimination Programme. Beijing, People\u2019s Medical Publishing House; 2022."},{"key":"4398_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nrmicro2239","volume":"7","author":"RT Eastman","year":"2009","unstructured":"Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7:864\u201374.","journal-title":"Nat Rev Microbiol"},{"key":"4398_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"4398_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"4398_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12936-019-2986-5","volume":"18","author":"SAS Diakite","year":"2019","unstructured":"Diakite SAS, Traore K, Sanogo I, Clark TG, Campino S, Sangare M, et al. A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in Mali. Malar J. 2019;18:361.","journal-title":"Malar J"},{"key":"4398_CR7","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D Menard","year":"2016","unstructured":"Menard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O. R, et al. A Worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med"},{"key":"4398_CR8","unstructured":"WHO. World Malaria Report. Geneva, World Health Organization; 2021."},{"key":"4398_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"4398_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","volume":"223","author":"V Asua","year":"2021","unstructured":"Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E. T et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J Infect Dis. 2021;223:985\u201394.","journal-title":"J Infect Dis"},{"key":"4398_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12936-020-3140-0","volume":"19","author":"X Wang","year":"2020","unstructured":"Wang X, Ruan W, Zhou S, Huang F, Lu Q, Feng X, et al. Molecular surveillance of Pfcrt and k13 propeller polymorphisms of imported Plasmodium falciparum cases to Zhejiang Province, China between 2016 and 2018. Malar J. 2020;19:59.","journal-title":"Malar J"},{"key":"4398_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1612765","volume":"376","author":"F Lu","year":"2017","unstructured":"Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991\u20133.","journal-title":"N Engl J Med"},{"key":"4398_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/1475-2875-9-374","volume":"9","author":"JM Sa","year":"2010","unstructured":"Sa JM, Twu O. Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the PfCRT SVMNT type. Malar J. 2010;9:374.","journal-title":"Malar J"},{"key":"4398_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12936-021-03859-z","volume":"20","author":"MC Mulenga","year":"2021","unstructured":"Mulenga MC, Sitali L, Ciubotariu II, Hawela MB, Hamainza B, Chipeta J, et al. Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia. Malar J. 2021;20:329.","journal-title":"Malar J"},{"key":"4398_CR15","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","volume":"9","author":"LS Ross","year":"2018","unstructured":"Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, et al. Emerging southeast asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018;9:3314.","journal-title":"Nat Commun"},{"key":"4398_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12936-020-03339-w","volume":"19","author":"N Boonyalai","year":"2020","unstructured":"Boonyalai N, Vesely BA, Thamnurak C, Praditpol C, Fagnark W, Kirativanich K, et al. Piperaquine resistant cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization. Malar J. 2020;19:269.","journal-title":"Malar J"},{"key":"4398_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13071-022-05239-1","volume":"15","author":"R Ye","year":"2022","unstructured":"Ye R, Zhang Y, Zhang D. Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in Plasmodium falciparum isolates from the China-Myanmar, Thailand-Myanmar, and Thailand-Cambodia borders. Parasit Vectors. 2022;15:130.","journal-title":"Parasit Vectors"},{"key":"4398_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","volume":"216","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. J Infect Dis. 2017;216:468\u201376.","journal-title":"J Infect Dis"},{"key":"4398_CR19","doi-asserted-by":"publisher","first-page":"e02655-16","DOI":"10.1128\/AAC.02655-16","volume":"61","author":"SM Chenet","year":"2017","unstructured":"Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vreden S, et al. Molecular profile of malaria drug resistance markers of Plasmodium falciparum in Suriname. Antimicrob Agents Chemother. 2017;61:e02655-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"4398_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14787210.2021.1962291","volume":"20","author":"C Rasmussen","year":"2022","unstructured":"Rasmussen C, Alonso P, Ringwald P. Current and emerging strategies to combat antimalarial resistance. Expert Rev Anti Infect Ther. 2022;20:353\u201372.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4398_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12879-018-3018-8","volume":"18","author":"J Feng","year":"2018","unstructured":"Feng J, Tu H, Zhang L, Zhang S, Jiang S, Xia Z, Zhou S. Mapping transmission foci to eliminate malaria in the People\u2019s Republic of China, 2010\u20132015: a retrospective analysis. BMC Infect Dis. 2018;18:115.","journal-title":"BMC Infect Dis"},{"key":"4398_CR22","doi-asserted-by":"publisher","first-page":"e0271720","DOI":"10.1128\/AAC.02717-20","volume":"65","author":"J Feng","year":"2021","unstructured":"Feng J, Xu D, Kong X, Lin K, Yan H, Feng X, Tu H, et al. Characterization of pfmdr1, pfcrt, pfK13, pfubp1, and pfap2mu in travelers returning from Africa with Plasmodium falciparum infections reported in China from 2014 to 2018. Antimicrob Agents Chemother. 2021;65:e0271720.","journal-title":"Antimicrob Agents Chemother"},{"key":"4398_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12936-021-03737-8","volume":"20","author":"W Cheng","year":"2021","unstructured":"Cheng W, Song X, Tan H, Wu K, Li J. Molecular surveillance of anti-malarial resistance pfcrt, pfmdr1, and pfk13 polymorphisms in african Plasmodium falciparum imported parasites to Wuhan, China. Malar J. 2021;20:209.","journal-title":"Malar J"},{"key":"4398_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.15212\/ZOONOSES-2021-1002","volume":"1","author":"J Feng","year":"2021","unstructured":"Feng J, Zhang L, Xia ZG, Zhou SS, Xiao N. Malaria-free certification in China: achievements and lessons learned from the national malaria elimination programme. Zoonoses. 2021;1:2.","journal-title":"Zoonoses"},{"key":"4398_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12936-018-2444-9","volume":"17","author":"J Feng","year":"2018","unstructured":"Feng J, Zhang L, Huang F, Yin JH, Tu H, Xia ZG, Zhou SS, Xiao N, Zhou XN. Ready for malaria elimination: zero indigenous case reported in the People\u2019s Republic of China. Malar J. 2018;17:315.","journal-title":"Malar J"},{"key":"4398_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4269\/ajtmh.14-0733","volume":"93","author":"J Feng","year":"2015","unstructured":"Feng J, Xiao H, Xia Z, Zhang L, Xiao N. Analysis of malaria epidemiological characteristics in the People\u2019s Republic of China, 2004\u20132013. Am J Trop Med Hyg. 2015;93:293\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"4398_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15212\/ZOONOSES-2021-1002","volume":"1","author":"JZL Feng","year":"2021","unstructured":"Feng JZL, Xia ZG, Zhou SS, Xiao N. Malaria-free certification in China: achievements and lessons learned from the national malaria elimination programme. Zoonoses. 2021;1:3\u20136.","journal-title":"Zoonoses"},{"key":"4398_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fpubh.2019.00095","volume":"7","author":"J Feng","year":"2019","unstructured":"Feng J, Kong X, Xu D, Yan H, Zhou H, Tu H, Lin K. Investigation and evaluation of genetic diversity of Plasmodium falciparum Kelch 13 polymorphisms imported from Southeast Asia and Africa in Southern China. Front Public Health. 2019;7:95.","journal-title":"Front Public Health"},{"key":"4398_CR29","doi-asserted-by":"publisher","first-page":"e00981-20","DOI":"10.1128\/AAC.00981-20","volume":"64","author":"H Yan","year":"2020","unstructured":"Yan H, Kong X, Zhang T, Xiao H, Feng X, Tu H, et al. Prevalence of Plasmodium falciparum Kelch 13 (PfK13) and ubiquitin-specific protease 1 (pfubp1) gene polymorphisms in returning travelers from Africa reported in Eastern China. Antimicrob Agents Chemother. 2020;64:e00981-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"4398_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12936-019-2984-7","volume":"18","author":"J Li","year":"2019","unstructured":"Li J, Shi Y, Zhang W, Yan H, Lin K, Wei S, et al. K13-propeller gene polymorphisms of Plasmodium falciparum and the therapeutic effect of artesunate among migrant workers returning to Guangxi, China (2014\u20132017). Malar J. 2019;18:349.","journal-title":"Malar J"},{"key":"4398_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1186\/s12879-021-06579-6","volume":"21","author":"X Jin","year":"2021","unstructured":"Jin X, Zhu S, Xu W, Chen J, Ruan W, Wang X. Limited polymorphism in k13 gene of Plasmodium falciparum and k12 of Plasmodium vivax isolates imported from african and asian countries between 2014 and 2019 in Hangzhou city, China. BMC Infect Dis. 2021;21:853.","journal-title":"BMC Infect Dis"},{"key":"4398_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/infdis\/jiv414","volume":"213","author":"O Maiga-Ascofare","year":"2016","unstructured":"Maiga-Ascofare O, May J. Is the A578S single-nucleotide polymorphism in K13-propeller a marker of emerging resistance to artemisinin among Plasmodium falciparum in Africa? J Infect Dis. 2016;213:165\u20136.","journal-title":"J Infect Dis"},{"key":"4398_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12879-022-07112-z","volume":"22","author":"DM Yobi","year":"2022","unstructured":"Yobi DM, Kayiba NK, Mvumbi DM, Boreux R, Kabututu PZ, Akilimali PZ, et al. Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019. BMC Infect Dis. 2022;22:145.","journal-title":"BMC Infect Dis"},{"key":"4398_CR34","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/tmi.13273","volume":"4","author":"U Igbasi","year":"2019","unstructured":"Igbasi U, Oyibo W, Omilabu S, Quan H, Chen SB, Shen HM, et al. Kelch 13 propeller gene polymorphism among Plasmodium falciparum isolates in Lagos, Nigeria: molecular epidemiologic study. Trop Med Int Health. 2019;4:1011\u20137.","journal-title":"Trop Med Int Health"},{"key":"4398_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1051\/parasite\/2016069","volume":"23","author":"AF Some","year":"2016","unstructured":"Some AF, Sorgho H, Zongo I, Bazie T, Nikiema F, Sawadogo A, Zongo M, et al. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite. 2016;23:60.","journal-title":"Parasite"},{"key":"4398_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ijantimicag.2017.01.032","volume":"49","author":"M Madamet","year":"2017","unstructured":"Madamet M, Kounta MB, Wade KA, Lo G, Diawara S, Fall M, et al. Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal. Int J Antimicrob Agents. 2017;49:754\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"4398_CR37","doi-asserted-by":"publisher","first-page":"e0264548","DOI":"10.1371\/journal.pone.0264548","volume":"17","author":"FV Ajogbasile","year":"2022","unstructured":"Ajogbasile FV, Oluniyi PE, Kayode AT, Akano KO, Adegboyega BB, Philip C, et al. Molecular profiling of the artemisinin resistance Kelch 13 gene in Plasmodium falciparum from Nigeria. PLoS ONE. 2022;17:e0264548.","journal-title":"PLoS ONE"},{"key":"4398_CR38","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12936-017-2128-x","volume":"16","author":"CA Bonnington","year":"2017","unstructured":"Bonnington CA, Phyo AP, Ashley EA, Imwong M, Sriprawat K, Parker DM, et al. Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar. Malar J. 2017;16:480.","journal-title":"Malar J"},{"key":"4398_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12936-018-2625-6","volume":"17","author":"M Iwagami","year":"2018","unstructured":"Iwagami M, Nakatsu M, Khattignavong P, Soundala P, Keomalaphet S, Lorpachan L, et al. Heterogeneous distribution of k13 mutations in Plasmodium falciparum in Laos. Malar J. 2018;17:483.","journal-title":"Malar J"},{"key":"4398_CR40","doi-asserted-by":"publisher","first-page":"e0214667","DOI":"10.1371\/journal.pone.0214667","volume":"14","author":"MC Pau","year":"2019","unstructured":"Pau MC, Pantaleo A, Tsamesidis I, Hoang H, Tuan Tran A, Hanh Nguyen TL, et al. Clinical impact of the two ART resistance markers, K13 gene mutations and DPC3 in Vietnam. PLoS ONE. 2019;14:e0214667.","journal-title":"PLoS ONE"},{"key":"4398_CR41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/infdis\/jiv752","volume":"213","author":"SM Chenet","year":"2016","unstructured":"Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, Talundzic E, et al. Independent emergence of the Plasmodium falciparum Kelch propeller domain mutant allele C580Y in Guyana. J Infect Dis. 2016;213:1472\u20135.","journal-title":"J Infect Dis"},{"key":"4398_CR42","doi-asserted-by":"publisher","first-page":"e51015","DOI":"10.7554\/eLife.51015","volume":"9","author":"LC Mathieu","year":"2020","unstructured":"Mathieu LC, Cox H, Early AM, Mok S, Lazrek Y, Paquet JC. Aet al. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. Elife. 2020;9:e51015.","journal-title":"Elife"},{"key":"4398_CR43","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S1473-3099(20)30228-0","volume":"20","author":"M Imwong","year":"2020","unstructured":"Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis. 2020;20:1470\u201380.","journal-title":"Lancet Infect Dis"},{"key":"4398_CR44","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1128\/AAC.04843-14","volume":"59","author":"J Feng","year":"2015","unstructured":"Feng J, Zhou D, Lin Y, Xiao H, Yan H, Xia Z. Amplification of pfmdr1, pfcrt, pvmdr1, and K13 propeller polymorphisms associated with Plasmodium falciparum and Plasmodium vivax isolates from the China-Myanmar border. Antimicrob Agents Chemother. 2015;59:2554\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"4398_CR45","doi-asserted-by":"publisher","first-page":"733788","DOI":"10.3389\/fcimb.2021.733788","volume":"11","author":"T Tang","year":"2021","unstructured":"Tang T, Xu Y, Cao L, Tian P, Shao J, Deng Y, et al. Ten-year molecular surveillance of drug-resistant Plasmodium spp. isolated from the China-Myanmar border. Front Cell Infect Microbiol. 2021;11:733788.","journal-title":"Front Cell Infect Microbiol"},{"key":"4398_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1590\/S0074-02762012000100018","volume":"107","author":"G Awasthi","year":"2012","unstructured":"Awasthi G, Satya Prasad GB, Das A. Pfcrt haplotypes and the evolutionary history of chloroquine-resistant Plasmodium falciparum. Mem Inst Oswaldo Cruz. 2012;107:129\u201334.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"4398_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12936-021-03657-7","volume":"20","author":"K Kassaza","year":"2021","unstructured":"Kassaza K, Long AC, McDaniels JM, Andre M, Fredrickson W, Nyehangane D, et al. Surveillance of Plasmodium falciparum pfcrt haplotypes in Southwestern Uganda by high-resolution melt analysis. Malar J. 2021;20:114.","journal-title":"Malar J"},{"key":"4398_CR48","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1186\/s12879-019-4523-0","volume":"19","author":"M Deutsch-Feldman","year":"2019","unstructured":"Deutsch-Feldman M, Aydemir O, Carrel M, Brazeau NF, Bhatt S, Bailey JA, et al. The changing landscape of Plasmodium falciparum drug resistance in the Democratic Republic of Congo. BMC Infect Dis. 2019;19:872.","journal-title":"BMC Infect Dis"},{"key":"4398_CR49","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"4398_CR50","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12936-020-03281-x","volume":"19","author":"FT Foguim","year":"2020","unstructured":"Foguim FT, Bogreau H, Gendrot M, Mosnier J, Fonta I, Benoit N, et al. Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against african Plasmodium falciparum isolates. Malar J. 2020;19:201.","journal-title":"Malar J"},{"key":"4398_CR51","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1128\/AAC.01793-10","volume":"55","author":"RT Eastman","year":"2011","unstructured":"Eastman RT, Dharia NV, Winzeler EA, Fidock DA. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother. 2011;55:3908\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"4398_CR52","doi-asserted-by":"publisher","first-page":"e00303-17","DOI":"10.1128\/mBio.00303-17","volume":"8","author":"SK Dhingra","year":"2017","unstructured":"Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, et al. A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine. mBio. 2017;8:e00303-17.","journal-title":"mBio"},{"key":"4398_CR53","doi-asserted-by":"publisher","first-page":"e02731-18","DOI":"10.1128\/mBio.02731-18","volume":"10","author":"SK Dhingra","year":"2019","unstructured":"Dhingra SK, Gabryszewski SJ, Small-Saunders JL, Yeo T, Henrich PP, Mok S, et al. Global spread of mutant PfCRT and its pleiotropic impact on Plasmodium falciparum multidrug resistance and fitness. mBio. 2019;10:e02731-18.","journal-title":"mBio"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04398-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04398-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T07:03:22Z","timestamp":1670137402000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04398-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4398"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04398-x","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,4]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the ethical committee of the National Institute of Parasitic Diseases, Chinese Centre for Disease Control and Prevention (NIPD, China CDC, No. 2019008).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}